U.S. – FDA Approves Bristol Myers Squibb’s ZEPOSIA® (Ozanimod), a New Oral Treatment for Multiple Sclerosis
In clinical trials, ZEPOSIA demonstrated efficacy on a key clinical marker of disease activity – annualized relapse rate (ARR) – as compared…
A Look at Your Multiple Sclerosis Treatment Plan
Your doctor will should want to start treatment right after you’re diagnosed. Learn more about what to consider when you…
Stuart Schlossman
See the latest open-label extension data for Ocrevus
Examine 2 years of controlled and 3+ years of open-label extension efficacy and safety data. View in Browser Important Safety Information…
Stuart Schlossman
CMSC INforMS: Use of DMTs Changing ‘Natural History’ of Relapsing MS, Study Says
Thursday, January 2, 2020 – Posted by: Elizabeth Porco Click HERE to Register for the MS Beacon Newsletter People with…
Stuart Schlossman
High cost of MS medicines forcing patients to take ‘drastic actions’ – STAT
By ED SILVERMAN @Pharmalot JANUARY 13, 2020 Click HERE to Register for the MS Beacon Newsletter THE high cost of multiple sclerosis…
Stuart Schlossman
Who’s Willing to Accept More DMT Risk, You or Your Neuro?
Dec 20, 2019 – By Ed Tobias As more high-efficacy disease-modifying therapies (DMTs) are being made available, people with multiple…
Stuart Schlossman
“Treating MS: A Simplified Strategy Boosts Patient and Provider Satisfaction”
Both the busy clinician and the overwhelmed patient benefit from a pointed approach to disease management. By: Aaron Boster, MD…
Stuart Schlossman
How to Find the Right MS Treatment
Diane Kramer, 35, knows all too well the challenges of finding the right multiple sclerosis (MS) treatment. When she was…
Stuart Schlossman
Biogen scores FDA nod for Tecfidera follow-up Vumerity as MS threats linger
by Eric Sagonowsky | Oct 30, 2019 Biogen on Wednesday scored FDA approval for new MS offering Vumerity. (Biogen) Biogen’s multiple sclerosis business…
Stuart Schlossman
Diagnosis and Symptoms of Secondary Progressive MS
If you have secondary progressive multiple sclerosis (#SPMS), you most likely started out with the relapsing-remitting type (#RRMS). The shift…
Stuart Schlossman
